Cardinal Health has closed its divestiture of its Cardinal Health China business to Shanghai Pharmaceuticals. The sale includes Cardinal Health’s pharmaceutical and medical products distribution business in China. The divestiture does not include Cardinal Health’s remaining businesses in China, including Cordis, its recently acquired patient recovery business, its medical sourcing team or other functions. The gross proceeds of the transaction are $1.2 billion; the net proceeds are...